DiaMedica Therapeutics Q1 2025 10-Q Filed
Ticker: DMAC · Form: 10-Q · Filed: May 13, 2025 · CIK: 1401040
| Field | Detail |
|---|---|
| Company | Diamedica Therapeutics Inc. (DMAC) |
| Form Type | 10-Q |
| Filed Date | May 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals, R&D
TL;DR
DiaMedica Q1 2025 10-Q is in: check R&D and G&A spend for the quarter.
AI Summary
DiaMedica Therapeutics Inc. filed its Q1 2025 10-Q report on May 13, 2025, for the period ending March 31, 2025. The company, focused on pharmaceutical preparations, reported financial data for the first quarter of 2025 and the corresponding period in 2024. Key financial metrics such as general and administrative expenses and research and development expenses were detailed for both periods.
Why It Matters
This filing provides investors with an update on DiaMedica's financial performance and operational expenses for the first quarter of 2025, crucial for assessing the company's ongoing development and financial health.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, DiaMedica Therapeutics faces inherent risks related to drug development, clinical trials, regulatory approvals, and market competition.
Key Numbers
- 20250331 — End of Reporting Period (Q1 2025)
- 20250513 — Filing Date (Date of 10-Q submission)
Key Players & Entities
- DiaMedica Therapeutics Inc. (company) — Filer of the 10-Q report
- 20250331 (date) — End of the reporting period
- 20250513 (date) — Date the report was filed
- MINNEAPOLIS (location) — City of company's business and mailing address
- 301 CARLSON PARKWAY (address) — Street address of company's business and mailing address
FAQ
What were DiaMedica's General and Administrative expenses for Q1 2025 compared to Q1 2024?
The filing indicates that General and Administrative expenses for the period from January 1, 2025, to March 31, 2025, are reported, with a comparative period for 2024 also available, though specific dollar amounts are not detailed in this excerpt.
What were DiaMedica's Research and Development expenses for Q1 2025 compared to Q1 2024?
The filing includes data for Research and Development expenses for the period January 1, 2025, to March 31, 2025, and the corresponding period in 2024, but the exact figures are not provided in this summary.
What is the fiscal year end for DiaMedica Therapeutics Inc.?
DiaMedica Therapeutics Inc.'s fiscal year ends on December 31.
What is the SIC code for DiaMedica Therapeutics Inc.?
The Standard Industrial Classification (SIC) code for DiaMedica Therapeutics Inc. is 2834, which corresponds to Pharmaceutical Preparations.
When was DiaMedica Inc. formerly known as DiaMedica Therapeutics Inc.?
The company was formerly known as DiaMedica Inc. and its name change to DiaMedica Therapeutics Inc. occurred on May 25, 2007.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding DiaMedica Therapeutics Inc. (DMAC).